Klar Yaggi, Director of the Yale Centers for Sleep Medicine and a person living with obstructive sleep apnea, shares his personal experience with Tirzepatide (Zepbound), the first GLP-1 medication FDA-approved for people with both sleep apnea and obesity
Mahmoud Nassar, MD, PhD, from the Department of Medicine, Division of Endocrinology, Diabetes and Metabolism at the Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, who was not involved in this research, noted the following about the study to Medical News Today : Using national Medicare data, the study employs a robust target trial emulation design and leverages rigorous propensity score matching to balance demographic and clinical factors
Rashes are uncommon but possible
(E) Bar graphs and dots summarize the acute effects of Ex-4c
That's why innovative products are becoming increasingly important